172@29@17@103!~!172@29@0@53!~!|news|tags|alembic-pharma.html|page-3|!~!news|moneycontrol|com!~!|controller|tag.php!~!is_mobile=false
alembic pharma
Jump to
128 Results Found
  • Alembic Pharma Q4 PAT seen up 55.6% YoY to Rs. 148.3 cr: KR Choksey Apr 23, 2018 03:27 PM IST

    Alembic Pharma Q4 PAT seen up 55.6% YoY to Rs. 148.3 cr: KR Choksey

    Net Sales are expected to increase by 21.2 percent Y-o-Y (up 7 percent Q-o-Q) to Rs. 898.8 crore, according to KR Choksey.

  • Alembic Pharma Q4 PAT seen up 0.3% YoY to Rs. 90 cr: HDFC Securities Apr 20, 2018 01:40 PM IST

    Alembic Pharma Q4 PAT seen up 0.3% YoY to Rs. 90 cr: HDFC Securities

    Net Sales are expected to increase by 6.3 percent Y-o-Y (down 6.6 percent Q-o-Q) to Rs. 780 crore, according to HDFC Securities.

  • Alembic Pharma gets 3 observations from USFDA for Gujarat plant Mar 21, 2018 11:11 AM IST

    Alembic Pharma gets 3 observations from USFDA for Gujarat plant

    Alembic Pharmaceuticals today said the US health regulator has made three observations after inspecting its formulation facility in Panelav, Gujarat.

  • Hold Alembic Pharma; target of Rs 530: ICICI Direct Nov 15, 2017 05:12 PM IST

    Hold Alembic Pharma; target of Rs 530: ICICI Direct

    ICICI Direct recommended hold rating on Alembic Pharma with a target price of Rs 530 in its research report dated November 09, 2017.

  • Hold Alembic Pharma; target of Rs 580: KR Choksey Jul 25, 2017 05:35 PM IST

    Hold Alembic Pharma; target of Rs 580: KR Choksey

    KR Choksey recommended hold rating on Alembic Pharma with a target price of Rs 580 in its research report dated July 21, 2017.

  • Hold Alembic Pharma; target of Rs 570: ICICI Direct Jul 25, 2017 03:32 PM IST

    Hold Alembic Pharma; target of Rs 570: ICICI Direct

    ICICI Direct has recommended hold rating on Alembic Pharma with a target price of Rs 570 in its research report dated July 21, 2017.

  • Minority investors seek seat on Alembic board, analysts say move unprecedented Jul 24, 2017 06:51 PM IST

    Minority investors seek seat on Alembic board, analysts say move unprecedented

    The regulations under the Companies Act, 2013 allow a small shareholder director on the board with the specific intent of having the interest of small shareholders represented in the decisions made by the board.

  • Buy Alembic Pharma; target of Rs 635: HDFC Securities Jul 24, 2017 01:31 PM IST

    Buy Alembic Pharma; target of Rs 635: HDFC Securities

    HDFC Securities is bullish on Alembic Pharma has recommended buy rating on the stock with a target price of Rs 635 in its research report dated July 20, 2017.

  • Alembic Pharma Q1 PAT may dip 16.70% YoY to Rs 86.3 cr: KR Choksey Jul 18, 2017 06:45 PM IST

    Alembic Pharma Q1 PAT may dip 16.70% YoY to Rs 86.3 cr: KR Choksey

    Net Sales are expected to decrease by 6.86 percent Q-o-Q (down 6.29 percent Y-o-Y) to Rs 689.5 crore, according to KR Choksey. Alembic Pharma to report net profit at 86.3 crore down 16.70% year-on-year.

  • Hold Alembic Pharma; target of Rs 605: ICICI Direct May 08, 2017 05:13 PM IST

    Hold Alembic Pharma; target of Rs 605: ICICI Direct

    ICICI Direct recommended hold rating on Alembic Pharma with a target price of Rs 605 in its research report dated May 04, 2017.

  • Buy Alembic Pharma; target of Rs 675: HDFC Securities May 04, 2017 05:54 PM IST

    Buy Alembic Pharma; target of Rs 675: HDFC Securities

    HDFC Securities is bullish on Alembic Pharma has recommended buy rating on the stock with a target price of Rs 675 in its research report dated May 03, 2017.

  • Stocks in the news: TCS, RBL Bank, IRB Infra, TVS Motor, Marico, Rel Infra, MT Educare May 03, 2017 08:13 AM IST

    Stocks in the news: TCS, RBL Bank, IRB Infra, TVS Motor, Marico, Rel Infra, MT Educare

    TCS | Wipro | RBL Bank | IRB Infrastructure | Sun Pharma Advanced Research | Oil India | TVS Motor | Tata Communications | Nestle India | Reliance Infrastructure | MT Educare | United Breweries | JM Financial | Shriram City Union Finance | Inox Leisure and Marico are stocks, which are in the news today.

  • Top buzzing midcap stocks to trade on April 25 Apr 25, 2017 01:12 PM IST

    Top buzzing midcap stocks to trade on April 25

    Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today -- BHEL, M&M, Rallis, Biocon, Indiabulls Housing Finance, Marksans Pharma, MCX, Alembic Pharma, Delta Corp, and Pincon Spirits.

  • Alembic Pharma Q4 PAT seen up 7.4% to Rs 92.9 cr: ICICI Securities Apr 17, 2017 01:04 PM IST

    Alembic Pharma Q4 PAT seen up 7.4% to Rs 92.9 cr: ICICI Securities

    Net Sales are expected to increase by 2.6 percent Q-o-Q (up 26.3 percent Y-o-Y) to Rs 791.1 crore, according to ICICI Securities. Alembic Pharma to report net profit at 71.3 crore up 66.6% quarter-on-quarter.

  • Nifty ends flat as investors stay cautious ahead of poll results Mar 10, 2017 04:27 PM IST

    Nifty ends flat as investors stay cautious ahead of poll results

    Investors ignored the exit polls announced on Thursday. The exit poll results were not clear as some media outlets predicted a majority for the ruling BJP while others showed gains but not majority in Uttar Pradesh. The state is an important metric as it gives most number of representatives in the Upper House of the Parliament.

  • Alembic Pharma soars 7% on USFDA inspection clearance Mar 10, 2017 02:48 PM IST

    Alembic Pharma soars 7% on USFDA inspection clearance

    The US drug regulator had inspected its Baroda unit between March 6 and 10 and issued no Form 483s for the same.

  • Sell Alembic Pharma; target of Rs 560: Axis Securities Apr 29, 2016 05:44 PM IST

    Sell Alembic Pharma; target of Rs 560: Axis Securities

    Axis Securities is bearish on Alembic Pharma has recommended reduce rating on the stock with a target price of Rs 560 in its research report dated April 28, 2016.

  • Hold Alembic Pharma; target of Rs 623: KRChoksey Apr 29, 2016 10:31 AM IST

    Hold Alembic Pharma; target of Rs 623: KRChoksey

    KRChoksey has recommended hold rating on Alembic Pharma with a target price of Rs 623 in its research report dated April 28, 2016.

  • Buy Alembic Pharma; target of Rs 790:ICICIDirect Jan 27, 2016 11:42 AM IST

    Buy Alembic Pharma; target of Rs 790:ICICIDirect

    ICICIDirect is bullish on Alembic Pharma and has recommended buy rating on the stock with a target price of Rs 790 in its research report dated January 21, 2016.

  • Sell Alembic Pharma; target of Rs 560: Axis Securities Jan 25, 2016 05:34 PM IST

    Sell Alembic Pharma; target of Rs 560: Axis Securities

    Axis Securities is bearish on Alembic Pharma and has recommended sell rating on the stock with a target price of Rs 560 in its research report dated January 22, 2016.

  • Stocks in news: Maruti, Tata Motors, Religare, IOC, Kotak May 04, 2015 08:05 AM IST

    Stocks in news: Maruti, Tata Motors, Religare, IOC, Kotak

    Maruti Suzuki | Tata Motors | Religare Enterprises | Nestle | Chambal Fertilisers | Noida Toll Bridge | Kotak Mahindra Bank | HCC | IDFC | Shoppers Stop | Tata Chemicals | NOCIL | Oberoi Realty | IOC | BPCL | HPCL and Mahindra & Mahindra are stocks, which are in the news today.

  • Alembic Pharma consolidated Dec '13 sales at Rs 484.89 crore Jan 23, 2014 01:55 PM IST

    Alembic Pharma consolidated Dec '13 sales at Rs 484.89 crore

    Alembic Pharmaceuticals has reported a sales turnover of Rs 484.89 crore and a net profit of Rs 65.93 crore for the quarter ended Dec '13

  • Expect further upmove in Alembic Pharma, says Jigar Shah Jan 01, 2014 11:17 AM IST

    Expect further upmove in Alembic Pharma, says Jigar Shah

    Jigar Shah of Kim Eng Securities is of the view that one may see further upmove in Alembic Pharmaceuticals.

  • Early gains for generics in Cymbalta patent expiry: Sources Dec 31, 2013 01:48 PM IST

    Early gains for generics in Cymbalta patent expiry: Sources

    Cymbalta, which is used to treat depression and anxiety disorders, lost patent protection on December 12.

  • Buy BOI, YES Bank, Alembic Pharma, Arvind : Dharmesh Kant Dec 23, 2013 11:54 AM IST

    Buy BOI, YES Bank, Alembic Pharma, Arvind : Dharmesh Kant

    Dharmesh Kant of Indianivesh Securities recommends buying Alembic Pharmaceuticals with a target of Rs 220 and Arvind with a target of Rs 136.

Sections